Drug Approval | February 19, 2022
Amneal expands injectables portfolio with four new products
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
It has a total of 50 ANDA approvals from USFDA
The tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency
Subscribe To Our Newsletter & Stay Updated
